Autres langues Bio-Path Holdings, Inc.

Actions

BPTH

US09057N4097

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/05/2024			Varia. 5j.	Varia. 1 janv.
3 ^USD	+10,70%		+6,01%	-67,60%

18/04	Bio-Path Holdings, Inc. Bio-Path Holdings Inc. annonce l'achèvement réussi de la deuxième cohorte à dose plus élevée de l'essai clinique de phase 1/1B du BP1002 chez des patients atteints de leucémie myéloïde aiguë (LMA) réfractaire/récidivante	CI
15/04	Bio-Path Holdings, Inc. élargit son portefeuille mondial de brevets	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	22/04
Bio-Path Closes $1.2 Million Share Offering	19/04
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-theMarket Under Nasdaq Rules	19/04
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	18/04
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients	18/04
Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	18/04
Bio-Path Holdings Expands Global Patent Portfolio	15/04
Bio-Path Holdings, Inc. Expands Global Patent Portfolio	15/04
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	05/04
Bio-Path Holdings Provides 2024 Clinical and Operational Update	02/04
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23	27/03
Bio Path : Failure to Satisfy Listing Rule - Form 8-K	13/03
Bio-Path Holdings Reports Full Year 2023 Financial Results	08/03
North American Morning Briefing : Stock Futures -2-	08/03
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	04/03
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024	01/03
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split	21/02
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory Relapsed Lymphoma and Refractory Relapsed Chronic Lymphocytic Leukemia Patients	11/01
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients	10/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Bio-Path Holdings, Inc.

Actions

BPTH

US09057N4097

Autres langues

Filtres